Novartis wins FDA approval for prostate cancer therapy
Over the current book year the total revenue will be 53.04 billion CHF (consensus estimates). This is slightly more than 2021's revenue of 52.88 billion CHF.
Historical revenues and results Novartis plus estimates 2021
The analysts expect for 2022 a net profit of 13.3 billion CHF. For this year the consensus of the result per share is a profit of 6.21 CHF. The PE-ratio therefore is 13.82.
Huge dividend Novartis
Analysts expect a dividend of 3.36 CHF per share. Thus the dividend yield equals 3.91 percent. The average dividend yield of the pharmaceutical companies equals a limited 1.37 percent.Novartis 's market capitalization is based on the number of outstanding shares around 193.75 billion CHF. 15
At 17.37 the stock trades 0.63 percent lower at 85.85 CHF.Historical stock prices Novartis2010-2022
ValueSpectrum.com News Wire & Equity Research: +31 084-0032-842
news@valuespectrum.com
Copyright analist.nl B.V.
All rights reserved. Any redistribution, duplication or archiving prohibited. analist.nl doesn't warrant the accuracy of any News Content provided and shall not be liable for any errors, inaccuracies or for any actions taken in reliance thereon.
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x
|
